Genetic Factors May Predispose People with MPNs to Cardiovascular Events
August 15th 2022The new report is believed to be among the first to examine cardiovascular risk in myeloproliferative neoplasms through a genetic lens. Mutations in the CALR gene may restore vascular dysfunction in some patients.
Read More
FDA Updates for the Week of August 8, 2022
August 13th 2022In a busy week, the FDA has approved additional indications for Enhertu, Myfembree and Nubeqa, as well as a tablet form of Calquence. The agency also approved Xofluza for children, issued an EUA for monkeypox vaccine in children, extended the review of omaveloxolone, set up advisory committee meeting for microbiota-based C. diff therapy, and priority review for elacestrant in breast cancer. Additionally, Novaliq submited NDA for dry eye treatment.
Read More
How Tech-Driven Solutions, CMS Proposed Rule Can Save Rural Medicaid Members
August 11th 2022In this second part of a two-part video series, Nathan Allen, Senior Vice President – Healthcare Provider Solutions at Firstsource, discusses Medicaid Redetermination for those who are Medicaid members, but are deemed to lose their coverage due to the upcoming expiration of COVID-19’s Public Health Emergency. Allen set a scope on Medicaid populations in rural settings and how they could be affected. However, there is hope through tech-based solutions and a proposed rule by CMS to prevent facility closures and preserve access to care for all affected Medicaid populations.
Watch
Medicaid Redetermination Solutions for Members Deemed to Lose Coverage From PHE Expiration
August 10th 2022Nathan Allen, Senior Vice President – Healthcare Provider Solutions at Firstsource, discusses Medicaid Redetermination for those who are Medicaid members, but are deemed to lose their coverage due to the upcoming expiration of COVID-19’s Public Health Emergency.
Watch
Biomarkers for Graft-Versus-Host Disease | Part 2
August 10th 2022Biomarkers can be used for many purposes — diagnosis, prognosis, projections for success of a treatment. Sophie Paczesny, M.D., Ph.D., a professor at the Hollings Cancer Center at the Medical University of South Carolina and an internationally recognized expert on biomarkers for graft-versus-host disease (GvHD), reviews a typology of biomarkers that groups them into five subtypes and discusses their use in GVHD.
Read More
Biomarkers for Graft-Versus-Host Disease | Part 1
August 10th 2022What is a biomarker? Sophie Paczesny, M.D., Ph.D., a professor at the Hollings Cancer Center at the Medical University of South Carolina and an internationally recognized expert on biomarkers for graft-versus-host disease (GvHD), explains.
Read More
The Healthcare Provisions in the Inflation Reduction Act
August 8th 2022Pharma, health insurers square off about the healthcare provisions in the Inflation Reduction Act that passed the Senate yesterday. The PhRMA was sharply critical of the provisions that would empower CMS to negotiate the prices of a selected number of drugs. AHIP praised the extension of more generous ACA premium subsidies.
Read More
Digital Transformation is the Revolutionary Change Healthcare Needs
August 8th 2022Due to one of the most challenging global crises in living memory and one that presented an acute challenge for the medical community, healthcare providers find themselves operating within an uncertain landscape. They are still managing the fallout of COVID-19 while also planning for the future.
Read More
FDA Updates for Week of Aug. 1, 2022
August 6th 2022The FDA has made several approvals this week, including Enhertu for HER2-low breast cancer, a steroid-free cream for plaque psoriasis and the first interchangeable biosimilar to Lucentis, as well as Stelara in children with psoriatic arthritis. The agency has issued a complete response letter for Nuplazid in Alzheimer’s psychosis. Regulators have accepted a BLA for a biosimilar of Actemra and scheduled a second advisory committee meeting for AMX0035 in ALS.
Read More
Zynteglo May Herald “New Dawn” of Many Seven-Figure Gene Therapies
August 5th 2022An OptumRx drug pipeline report highlights Zynteglo, a curative gene therapy treatment for beta-thalassemia, and Skysona, a gene therapy for a cerebral adrenoleukodystrophy. FDA approval decision are imminent for both. Price tags of $2 million are expected.
Read More
Public Citizen Advises US Decision-Makers Investigate Amazon-One Medical Merger
August 4th 2022Public Citizen advised Amazon's acquisition of One Medical should be rejected if Amazon does not commit to robust, legally binding safeguards in a letter sent today to authorized U.S decision-makers.
Read More
Dr. Reddy’s Launches Prescription and Nonprescription Generics
August 1st 2022The prescription drug launches include a therapy to treat adults with multiple myeloma and a treatment for overactive bladder. Dr. Reddy’s has also acquired several therapies from Eton Pharmaceuticals, including hypotension treatments.
Read More
FDA Update for Week of July 25
July 30th 2022The FDA has approved lupus therapy for children and allows importation of contrast medium. The agency has accepted applications for several therapies, including for a Tysabri biosimilar, a therapy for a genetic form of ALS, and an immunotherapy for bladder cancer, as well as for Enhertu in low HER2 breast cancer. Additionally, AbbVie seeks additional indication for Rinvoq.
Read More
Telehealth Services May be Extended Under Medicare After Bill Passes Through House of Rep.
July 29th 2022The House of Representatives recently passed a bill this week that continues telehealth use under Medicare through 2024 that was initially authorized during the the height of the COVID-19 pandemic.
Read More
3 Growth Strategies for Healthcare Providers in 2022
July 28th 2022The healthcare sector has always been one of constant change, regularly experiencing technological, policy, and practice transformation. But the level of uncertainty and complexity since the pandemic hit has put understanding how the business of healthcare has changed on life support.
Read More